List of Kovanaze drug patents

Kovanaze is owned by St Renatus.

Kovanaze contains Oxymetazoline Hydrochloride; Tetracaine Hydrochloride.

Kovanaze has a total of 2 drug patents out of which 0 drug patents have expired.

Kovanaze was authorised for market use on 29 June, 2016.

Kovanaze is available in spray, metered;nasal dosage forms.

Kovanaze can be used as method of anesthetizing at least a portion of the maxillary dental arch.

The generics of Kovanaze are possible to be released after 02 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308191 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Apr, 2030

(7 years from now)

US8580282 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Apr, 2030

(7 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 June, 2016

Treatment: Method of anesthetizing at least a portion of the maxillary dental arch

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic